Skip to main content

Table 1 Analysis of PIK3CA mutations per exon and treatment group

From: Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

  Group A Group B Group C Group D Overall (pooled groups)
Exon
n (Mut/total)
pCR, n (%) non-pCR, n (%) pCR, n (%) non-pCR, n (%) pCR, n (%) non-pCR, n (%) pCR, n (%) non-pCR, n (%) pCR, n (%) non-pCR, n (%)
Exon 7 n = 2 n = 1 n = 1 n = 0 n = 4
(4/290) 0 2 (100) 0 1 (100) 0 1 (100) 0 0 0 4 (100)
Exon 9 n = 8 n = 5 n = 5 n = 10 n = 28
(28/328) 0 8 (100) 1 (20.0) 4 (80.0) 0 5 (100) 1 (10.0) 9 (90.0) 2 (7.1) 26 (92.9)
Exon 20 n = 20 n = 15 n = 17 n = 14 n = 66
(66/338) 7 (35.0) 13 (65.0) 7 (46.7) 8 (53.3) 2 (11.8) 15 (88.2) 3 (21.4) 11 (78.6) 19 (28.8) 47 (71.2)
  1. Mut mutant, pCR pathologic complete response, PIK3CA gene encoding phosphoinositide 3-kinase, catalytic subunit